Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donor-Derived Cell-Free DNA as a Prognostic Biomarker After Heart Transplantation: The DEFINE-HT Study.

JACC. Heart failure·2026
Same author

Utility of Right Ventricular Mass Ratios in Recipients With Pulmonary Hypertension: A United Network for Organ-Sharing Database Analysis.

Clinical transplantation·2026
Same author

Longitudinal Peripheral Blood Transcriptomics Reveal Novel Signatures During Cardiac Allograft Rejection.

Transplantation direct·2026
Same author

Sex differences in the association of vascular risk and APOE Genotype with cognitive decline and dementia: evidence from a U.S. longitudinal study.

Lancet regional health. Americas·2026
Same author

The U.S. diabetes belt and factors explaining the excess risk: Multifactorial modeling and machine learning analysis.

Primary care diabetes·2025
Same author

Trends in Left Ventricular Assist Device Utilization and Survival Outcomes Following the Donor Allocation Policy Change.

Artificial organs·2025

Related Experiment Video

Updated: Jul 14, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Immunosuppression on the horizon.

Howard J Eisen1

  • 1Drexel University College of Medicine, Philadelphia, PA 19102, USA. heisen@drexelmed.edu

Heart Failure Clinics
|June 5, 2007
PubMed
Summary

New immunosuppressive agents and strategies aim to reduce transplant toxicity and improve long-term outcomes. These approaches may minimize side effects like nephrotoxicity and cardiac allograft vasculopathy, offering hope for better patient recovery.

Area of Science:

  • Immunology
  • Nephrology
  • Cardiology
  • Transplantation Medicine

Background:

  • Novel immunosuppressive agents are in clinical trials.
  • Established immunosuppressants are being explored with modified dosing strategies.
  • Minimizing immunosuppression post-transplantation is a key goal to reduce toxicity.

Purpose of the Study:

  • To explore novel immunosuppressive agents and strategies for transplantation.
  • To reduce the toxicity associated with immunosuppressive therapy.
  • To improve long-term outcomes in transplant recipients, including cardiac allograft vasculopathy and malignancy.

Main Methods:

  • Clinical investigation of novel immunosuppressive agents.
  • Development of creative approaches for established immunosuppressive agents.

More Related Videos

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance
14:01

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance

Published on: July 22, 2011

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Related Experiment Videos

Last Updated: Jul 14, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance
14:01

Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance

Published on: July 22, 2011

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

  • Focus on minimizing immunosuppression early post-transplantation.

    • Main Results:

    • Evidence suggests reduced nephrotoxicity of calcineurin inhibitors with specific approaches.
    • Newer agents like proliferation signal inhibitors may ameliorate cardiac allograft vasculopathy and malignancy.
    • Costimulatory pathway inhibitors and other novel agents show potential for low long-term maintenance immunosuppression.

    Conclusions:

    • Novel immunosuppressive strategies hold promise for reducing transplant-related toxicities.
    • These advancements may mitigate long-term complications of cardiac transplantation.
    • The goal is to achieve effective immunosuppression with minimal long-term maintenance therapy.